Elicio Therapeutics, Inc. has announced the execution of an At Market Issuance Sales Agreement with B. Riley Securities, Inc., JonesTrading Institutional Services LLC, and Ladenburg Thalmann & Co. Inc. This agreement allows the company to issue and sell shares of its common stock, with an aggregate offering price of up to $100 million. The sales will be conducted at the company's discretion, utilizing its existing registration statement on Form S-3. The company will pay the agents a commission of 3% on the gross sales proceeds from any shares sold under this agreement. The agreement provides Elicio with a flexible financing option, enabling it to raise capital as needed while minimizing dilution risk. The company is not obligated to sell any shares under this agreement, and it retains the right to terminate the agreement with three days' notice. This strategic move is expected to enhance Elicio's liquidity position, allowing it to fund ongoing operations and potential growth initiatives. The company has also terminated a previous sales agreement with JonesTrading, which allowed for the sale of up to $40 million in common stock. This termination was executed without penalties, indicating a strategic shift in Elicio's approach to capital raising. The new agreement is seen as a positive step towards strengthening the company's financial foundation and supporting its long-term strategic goals.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.